Kamada Ltd. KMDA PHARMA
Company Overview
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Why Investors Should Care
Revenue has grown at a 11.7% CAGR over the past five years.
Trades at a P/E of 21.8, below the sector median of 24.8.
Operating margin of 17.3% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $180.46M (+12.1% YoY); net profit $20.20M.
- Trailing 12 Months Year-on-year growth — revenue +22.7%, earnings +23.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.74% |
| 1 Year: | 22.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 23.10% |
Stock Price Performance
| 1 Year: | +15.74% |
| 6 Months: | -2.92% |
| 3 Months: | +16.87% |
| 1 Month: | +16.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.35 · Neutral
P/E of 21.82 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.7% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KMDA Kamada Ltd. PHARMA | 8.29 | 21.82 | $478.42M | 1.96% | 7.92% | 8.40% | 11.74% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 44.02M | 44.75M | 47.01M | 44.68M | 45.24M |
| Cost of Revenue | - | 23.27M | 25.82M | 27.25M | 27.71M | 26.12M |
| Gross Profit | - | 20.75M | 18.93M | 19.76M | 16.97M | 19.12M |
| Operating Expenses | - | 12.95M | 11.86M | 11.95M | 13.42M | 12.16M |
| Operating Income | - | 7.79M | 7.07M | 7.82M | 3.55M | 6.95M |
| EBITDA | - | 10.42M | 9.69M | 10.35M | 8.79M | 9.43M |
| Interest Expense | - | 192.00K | 192.00K | 221.00K | 259.00K | 188.00K |
| Pretax Income | - | 6.61M | 5.75M | 6.37M | 4.73M | 5.39M |
| Tax Provision | - | 2.65M | -1.62M | 1.07M | 1.17M | 1.26M |
| Net Income | - | 3.96M | 7.38M | 5.30M | 3.56M | 4.13M |
| Diluted EPS | - | 0.07 | 0.13 | 0.09 | 0.06 | 0.07 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 129.34M | 142.52M | 160.95M | 180.46M |
| Cost of Revenue | - | 82.64M | 87.03M | 90.99M | 104.05M |
| Gross Profit | - | 46.70M | 55.49M | 69.97M | 76.41M |
| Operating Expenses | - | 42.17M | 45.43M | 49.92M | 50.17M |
| Operating Income | - | 4.53M | 10.06M | 20.05M | 26.23M |
| EBITDA | - | 10.81M | 22.44M | 27.80M | 39.25M |
| Interest Expense | - | 914.00K | 1.30M | 660.00K | 864.00K |
| Pretax Income | - | -2.26M | 8.43M | 13.33M | 23.47M |
| Tax Provision | - | 62.00K | 145.00K | -1.13M | 3.27M |
| Net Income | - | -2.32M | 8.28M | 14.46M | 20.20M |
| Diluted EPS | - | -0.05 | 0.15 | 0.25 | 0.35 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 322.38M | 354.91M | 372.25M | 378.71M |
| Current Assets | - | 139.00M | 169.96M | 184.35M | 193.07M |
| Cash & Equivalents | - | 34.26M | 55.64M | 78.44M | 75.47M |
| Inventory | - | 72.52M | 88.48M | 78.82M | 84.94M |
| Receivables | - | 27.13M | 19.73M | 21.39M | 27.01M |
| Total Liabilities | - | 146.36M | 110.89M | 112.79M | 109.64M |
| Current Liabilities | - | 75.70M | 49.59M | 49.39M | 47.39M |
| Long Term Debt | 17.41M | 12.96M | - | - | - |
| Total Debt | - | 20.60M | 8.82M | 11.06M | 11.56M |
| Total Equity | - | 176.02M | 244.02M | 259.46M | 269.07M |
| Shares Outstanding | - | 44.83M | 57.48M | 57.51M | 57.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 28.59M | 4.32M | 47.59M | 25.49M |
| Investing Cash Flow | - | -3.78M | -5.84M | -10.74M | -9.84M |
| Financing Cash Flow | - | -9.34M | 22.68M | -13.91M | -18.34M |
| Capital Expenditure | - | -3.78M | -5.85M | -10.74M | -9.85M |
| Free Cash Flow | - | 24.80M | -1.53M | 36.85M | 15.64M |
| Net Change in Cash | - | 15.46M | 21.15M | 22.94M | -2.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 36.1% | 38.9% | 43.5% | 42.3% |
| Operating Margin % | - | 3.5% | 7.1% | 12.5% | 14.5% |
| Net Margin % | - | -1.8% | 5.8% | 9.0% | 11.2% |
| ROE % | - | -1.3% | 3.4% | 5.6% | 7.5% |
| ROCE % | - | 1.8% | 3.3% | 6.2% | 7.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Phoenix Financial Ltd. | 2.87% | 1.65M | $14.65M |
| 2 | Renaissance Technologies, LLC | 1.29% | 742.42K | $6.57M |
| 3 | Wells Fargo & Company | 1.03% | 592.06K | $5.24M |
| 4 | Dimensional Fund Advisors LP | 0.52% | 301.68K | $2.67M |
| 5 | ARK Investment Management, LLC | 0.46% | 263.30K | $2.33M |
| 6 | Huntleigh Advisors, Inc. | 0.28% | 162.64K | $1.44M |
| 7 | Acadian Asset Management. LLC | 0.27% | 154.38K | $1.37M |
| 8 | Two Sigma Investments, LP | 0.26% | 151.10K | $1.34M |
| 9 | Renaissance Group, LLC | 0.22% | 124.90K | $1.11M |
| 10 | Marshall Wace LLP | 0.13% | 75.18K | $665.36K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KMDA
Stock option move leaves Kamada (KMDA) exec with 865 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQMDdrdlNCa3FyZHM3SjVkbEZmZkxrRzlxRXN4eUFUSk1sTm5xNDRVNkFmX0k2VXpNU0lUbWNqQnZlMTUzdGxncXVJUjk5OVdkTERaRGJ5UDNpaHh1STNTOGx0ZUNYRVFyYkVjZ243M3AwczZPbHB4RkZyYXlLeDEwMkZycjJpanFqNzJZX2…
Kamada Stock Price Forecast. Should You Buy KMDA? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9DdERhSFljUWpQU0ZUYUg1bkp3Q1l4a2FieXBubTlqc2RCQmpIWjF1ZUFpX1FXNi1ScE5DcXZQRWE1NkFPYnVpRw?oc=5" target="_blank">Kamada Stock Price Forecast. Should You Buy KMDA?</a> <fon…
Should Value Investors Buy Kamada (KMDA) Stock? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOZnBJYXk5bmdsdmNzSnRqVjZaV0g1c2hkV2FpY0R4Y1d0UGVaRFF6eGl6Unkxc0w4cGtMaGtNU0JsdG1nRjZialNYR2VCQ0NkM2c4aHR2ZW9mXzhKeHluWVlOZ3RmSWdERE1YalZGQTFKSG9kcURPVDJHUkNCOG45OUg0VTFWRER5Tl9Tcn…
Director At Kamada Exercises Options Worth $77K - Benzinga
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOVmxkWVltZVdQOXhSRVJHUHFKcV83cEZKaHJzclRDWDJvYnJFV0E1alExTWNVY0pnb3ZTMW8tRG9SS0RzXy1VR3NZNTZmWlBLbmZPTEwwZnNGQVRhN1dRSjdWU2hwV3VCZkRvOTVGMnJaVGhLQlRSMTUyQzBVRDJZblZZc3lMT0dJY000ZG…
Why (KMDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQN0pJYW83OWIwUHBraklpWEhNeFh0M2MtelkwMVc1ZEt6MlJhY1g1eTJiWU43SlVRRkk4cVVMVUE5UHluMWwyaEhhTWVDNEVEMDRteW5PTmZYTGprSEllbFZHWERUS0gxTGNnU3RndFRPSHIzN1E3LW1zTUJlRDc2Zk9BQ1ZJeFVfMWY3RT…
Kamada shareholders can seek lower tax on a $0.17 dividend. Forms are due Oct. 7. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNVlJPMzQwY3ZJaFhNRWxiOFNFS2ZvNy1DUXdjd0J4dVFfdkNiN2lrZ1lINXFLbWIwVzk0WUR4NnlKVnRYYkFuSE44NUp6VEktNlJRMTNfOVpkQjBOZWloNF81UENSWUNVTzZKbDBKZDdXb2FXb2UtX2RNYlQyOTd4UTdUYWJHNTh5enpuNH…
KMDA — Frequently Asked Questions
What is the current share price of Kamada Ltd. (KMDA)?
As of 2026-09-19 21:16 PDT, Kamada Ltd. (KMDA) trades at $8.29 on NasdaqGS. Its 52-week range is $6.28 to $8.85.
What is the market capitalisation of KMDA?
Kamada Ltd. (KMDA) has a market capitalisation of $478.42M on NasdaqGS.
What is the P/E ratio of KMDA?
KMDA trades at a trailing price-to-earnings (P/E) ratio of 21.82. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.90.
Does KMDA pay a dividend?
Kamada Ltd. (KMDA) currently offers a dividend yield of 1.96%.
What is the return on equity (ROE) of KMDA?
KMDA has a return on equity (ROE) of 8.40%. Its return on capital employed (ROCE) is 7.92%.
Is KMDA a good stock to buy?
This page provides a data-driven analysis of Kamada Ltd. (KMDA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.